Core Viewpoint - The approval of the antibody-drug conjugate sac-TMT (also known as SKB264/MK-2870) for a new indication in treating HR+/HER2- breast cancer patients in China marks a significant milestone for the company, expanding its therapeutic applications in oncology [1] Group 1: Regulatory Approval - The National Medical Products Administration (NMPA) of China has approved sac-TMT for treating adult patients with unresectable or metastatic HR+/HER2- breast cancer who have previously received endocrine therapy and at least one line of chemotherapy [1] - This approval represents the fourth indication for sac-TMT in China [1] Group 2: Clinical Study Results - The approval is based on positive results from the OptiTROP-Breast023 phase II clinical study, which was presented at the 2025 European Society for Medical Oncology (ESMO) conference [1] - The OptiTROP-Breast02 study evaluated the efficacy and safety of sac-TMT compared to investigator-selected chemotherapy in patients with unresectable or metastatic HR+/HER2- breast cancer, with 95.7% of patients having visceral metastases and 75.9% having liver metastases at enrollment [2] - The study showed a significant improvement in progression-free survival (PFS) for the sac-TMT group compared to the chemotherapy group (8.3 months vs. 4.1 months; hazard ratio (HR), 0.35; 95% confidence interval (CI): 0.26-0.48; p<0.0001) [2] - Consistent PFS benefits were observed across predefined subgroups, including those with different HER2 expression levels and prior chemotherapy lines [2] - The overall survival (OS) benefit trend and objective response rate (ORR) were also significantly improved in the sac-TMT group (41.5% vs. 24.1%) [2] Group 3: Ongoing Research - Ongoing phase III clinical studies are investigating sac-TMT, with or without pembrolizumab, for HR+/HER2- breast cancer patients who have previously received endocrine therapy but not chemotherapy, both globally and in China [3]

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 四川科倫博泰生物醫藥股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6990） 自願公告 核心產品TROP2 ADC蘆康沙妥珠單抗(sac-TMT) 獲 國 家 藥 品 監 督 管 理 局 批 准 第 四 項 適 應 症 上 市， 用於治療2L+ HR+/HER2-乳腺癌 四 川 科 倫 博 泰 生 物 醫 藥 股 份 有 限 公 司（「本公司」）董 事（「董 事」）董 事 會（「董 事 會」）欣 然 宣 佈，近 日，本 公 司 靶 向 人 滋 養 細 胞 表 面 抗 原2(TROP2)的抗體 偶聯藥物(ADC)蘆 康 沙 妥 珠 單 抗（sac-TMT，亦稱SKB264/MK-2870）（佳 泰 萊®） 的一項新增適應症上市申請 已獲中國國家藥品監督管理局(NMPA)批 准， 用於治療既往接受過內分泌治療且在晚期疾病階段接受過至少一線化療 的不可切除或轉移性的激素受體陽性(HR+)且人類表皮生長因子受體2陰 性（HER2-）（免 疫 組 織 化 ...

Core Viewpoint - Yunding Xinyao's core product VELSIPITY has received approval from the NMPA for treating moderate to severe active ulcerative colitis (UC) in adults, filling a significant gap in treatment options and is expected to generate peak sales of 5 billion RMB [1][6]. Group 1: Product Approval and Market Potential - VELSIPITY is a new generation S1P receptor modulator that offers rapid onset and effective mucosal healing, providing a new first-line treatment option for UC patients [1][3]. - The approval of VELSIPITY is anticipated to drive significant growth for Yunding Xinyao, marking a major breakthrough in the autoimmune disease sector [6][7]. - The drug's peak sales potential is projected to reach 5 billion RMB, contributing to the company's revenue growth alongside existing products [6][7]. Group 2: Clinical Efficacy and Guidelines - Clinical studies have shown VELSIPITY's efficacy, with a clinical remission rate of 48.1% and a mucosal healing rate of 51.9% after 40 weeks of treatment [3][4]. - VELSIPITY has been included in major international clinical guidelines as a first-line treatment for UC, reflecting its recognized clinical value [4][5]. Group 3: Commercialization Strategy - Yunding Xinyao has established a comprehensive A2MS operational system to efficiently promote VELSIPITY's market entry and clinical application [5][6]. - The company aims to accelerate the commercialization process and integrate VELSIPITY into the national medical insurance directory to enhance accessibility for patients [1][6]. Group 4: Future Growth and Strategic Goals - Yunding Xinyao's 2030 strategic goal includes achieving over 15 billion RMB in revenue and expanding its product portfolio to over 20 commercialized products [6][7]. - The company expects a compound annual growth rate of over 50% from 2025 to 2030, with a focus on both BD collaborations and independent research and development [7].

Core Viewpoint - The company plans to establish an industrial merger and acquisition fund named Heyuan Hongsheng Industrial Investment Fund Partnership, focusing on investments in the cell and gene therapy industry chain and related upstream and downstream sectors [1] Fund Details - The targeted fundraising scale for the fund is set at 500 million yuan, with the company intending to contribute no more than 100 million yuan of its own funds, representing approximately 20% of the total fundraising scale [1]

Core Viewpoint - Yiteng Jiahe (06998) has completed a reverse acquisition with Jiahe Biotechnology, marking the official establishment of Yiteng Jiahe and entering a new phase of strategic integration and development [5]. Group 1: Stock Performance - Yiteng Jiahe's stock price rose by 6.04% to HKD 2.81, with an intraday increase exceeding 9% and a trading volume of HKD 9.8047 million [5]. Group 2: Corporate Actions - The reverse acquisition was finalized on December 30, and the Chinese stock abbreviation for Jiahe Biotechnology will change from "嘉和生物" to "亿腾嘉和," effective from February 6, 2026 [5]. - Jiahe Biotechnology announced plans to repurchase shares in the open market, with a total repurchase amount of approximately HKD 18.517 million and 7.245 million shares repurchased as of February 5 [5].

Group 1 - The core point of the news is the management changes at XinNuoWei, with Yao Bing resigning as General Manager and Dai Long being appointed as the new General Manager, while Xu Wen is appointed as the Board Secretary [1] - Dai Long, who was previously the Financial Director, has been with the company since December 2016 and has held various positions including Financial Manager and Board Secretary [2] - Xu Wen, with a master's degree, has experience in the pharmaceutical industry and has served in senior roles at other companies before joining XinNuoWei [2] Group 2 - XinNuoWei's latest earnings forecast indicates a projected net loss of 170 million to 255 million yuan for 2025, compared to a profit of 53.73 million yuan in the same period last year [5] - The reasons for the expected loss include increased R&D expenses due to significant progress in multiple products, the impact of acquiring minority stakes in a subsidiary, and a decrease in profit margins for caffeine products [5] - As of February 6, 2026, XinNuoWei's A-share price is reported at 35.07 yuan, with a total market capitalization of 49.287 billion yuan [5]

Core Viewpoint - The approval of VELSIPITY for the treatment of moderate to severe active ulcerative colitis (UC) in adults marks a significant milestone for the company and aligns with its 2030 development strategy [1] Group 1: Company Developments - The company’s stock rose over 5% in the afternoon trading session, currently up 3.4% at HKD 40.18, with a trading volume of HKD 151 million [1] - The National Medical Products Administration (NMPA) of China has approved the new drug application for VELSIPITY, which is intended for patients who have inadequate response, loss of response, or intolerance to traditional therapies or biological agents [1] - The company plans to actively prepare for the commercialization of VELSIPITY and aims to expedite the availability of this therapy to domestic patients while pushing for its inclusion in the national medical insurance catalog [1] Group 2: Strategic Goals - The approval of VELSIPITY is a crucial part of the company's 2030 development strategy, which emphasizes a dual approach of "BD collaboration + self-research" to create certain value through commercialization and growth value through research and development [1] - The company aims to strengthen its core therapeutic area advantages, advance innovative drug research and commercialization, and establish a sustainable growth model as a global innovative biopharmaceutical enterprise [1]

Core Viewpoint - The approval of VELSIPITY® for the treatment of moderate to severe active ulcerative colitis (UC) in adults marks a significant milestone for the company and aligns with its 2030 development strategy [1] Company Developments - The National Medical Products Administration (NMPA) of China has approved the new drug application for VELSIPITY® (Arginine Acquimod Tablets) [1] - The company plans to actively prepare for the commercialization of VELSIPITY® and aims to expedite its availability to domestic patients while promoting its inclusion in the national medical insurance catalog [1] Strategic Goals - The approval of VELSIPITY® is part of the company's broader 2030 development strategy, which emphasizes a dual approach of "BD collaboration + self-research" to create both certain commercial value and growth-oriented research and development value [1] - The company intends to continue strengthening its core therapeutic area advantages, advancing innovative drug research and commercialization, and establishing itself as a sustainable growth global innovative biopharmaceutical enterprise [1]

Core Insights - The approval of VELSIPITY® (Argenine Acquimod Tablets) by the NMPA marks a significant milestone for the company in the autoimmune field, providing a new first-line treatment option for adult patients with moderate to severe active ulcerative colitis (UC) who have inadequate response to traditional therapies or biologics [1][2] - The company aims to commercialize VELSIPITY® quickly and is actively working to include it in the national medical insurance directory, aligning with its 2030 development strategy focused on dual-driven growth through BD collaboration and self-research [2][4] Group 1: Product and Clinical Research - VELSIPITY® is a next-generation high-selectivity sphingosine-1-phosphate (S1P) receptor modulator, administered once daily, demonstrating rapid onset and strong mucosal healing with good safety characteristics [1] - The approval is based on results from the largest Asian Phase III registration clinical study (ENLIGHTUC) involving 340 patients, as well as global Phase III studies (ELEVATEUC52 and ELEVATEUC12) that confirmed the drug's favorable benefit-risk profile [1][2] Group 2: Commercialization Strategy - The company has established a commercialization platform with three products and is focused on building a comprehensive commercialization system and drug lifecycle management capabilities [3] - Revenue targets include exceeding 10 billion RMB by 2028 and over 15 billion RMB by 2030, with an expected compound annual growth rate of over 50% from 2025 to 2030 [3] Group 3: Future Growth and Strategic Goals - The 2030 development strategy emphasizes a dual-driven approach of BD collaboration and self-research, aiming to introduce 3 to 5 late-stage blockbuster products annually and achieve peak sales within three years post-reimbursement [4] - The company plans to introduce over 20 high-value assets by 2030, contributing approximately 6 billion RMB in revenue, with a long-term goal of reaching around 30 billion RMB by 2035 [4]

Core Insights - The approval of Velsipity (Arginine Acumod Tablets) by the NMPA marks a significant milestone for the company in establishing its leading position in the autoimmune field [1][3] - Velsipity is a new generation high-selectivity S1P receptor modulator that offers a new first-line treatment option for adult patients with moderate to severe active ulcerative colitis [2] - The company aims to commercialize Velsipity quickly and push for its inclusion in the national medical insurance directory as part of its 2030 development strategy [3] Clinical Research - The approval is based on results from the ENLIGHT UC study, the largest Phase III registration clinical trial for moderate to severe active ulcerative colitis patients in Asia, involving 340 patients [2] - Velsipity demonstrated statistical significance and clinical relevance in all primary and secondary efficacy endpoints during the 12-week induction and 40-week maintenance treatment periods [2] - The ELEVATE UC Phase III studies further validated Velsipity's favorable benefit-risk profile [2] Commercialization Strategy - The company has laid out plans to establish a comprehensive commercialization system and aims to achieve revenue exceeding 10 billion RMB by 2028 and over 15 billion RMB by 2030 [4] - The revenue growth rate is projected to exceed 50% from 2025 to 2030, with a target of maintaining over 15% growth post-2030 [4] - The number of commercialized products is expected to increase to over 20, including Velsipity and other key products [4] Future Development Plans - The 2030 development strategy signifies a crucial milestone for the company in advancing towards the forefront of global biopharmaceuticals [5] - The company plans to introduce 3 to 5 late-stage blockbuster products annually and aims to contribute 6 billion RMB in revenue from over 20 high-value assets by 2030 [5] - The strategic focus will be on maintaining leadership in core therapeutic areas and innovative drug development, aiming to become a leading comprehensive biopharmaceutical company globally [5]